Frontiers in Endocrinology (Aug 2022)

A systematic review and meta-analysis of endocrine-related adverse events associated with interferon

  • Linghuan Wang,
  • Linghuan Wang,
  • Binqi Li,
  • Binqi Li,
  • He Zhao,
  • Peixin Wu,
  • Qingzhen Wu,
  • Kang Chen,
  • Yiming Mu,
  • Yiming Mu

DOI
https://doi.org/10.3389/fendo.2022.949003
Journal volume & issue
Vol. 13

Abstract

Read online

ObjectivesTo perform a systematic review and meta-analysis of interferon and endocrine side effects, including their incidence, evaluation, and management.MethodsPubMed was searched through March 7th, 2021, by 2 authors independently (LH Wang and H Zhao). Early phase I/II, phase III experimental trials, prospective and retrospective observational studies were included. Stata 16.0 (StataCorp LLC, 16.0) was the main statistical software for meta-analysis. The weighted incidence and risk ratio were estimated for primary thyroid disease and diabetes mellitus.ResultsA total of 108 studies involving 46265 patients were included. Hypothyroidism was the most common thyroid disorder, followed by hyperthyroidism. IFN α+RBV treated patients experienced hypothyroidism in 7.8% (95%CI, 5.9-9.9), which was higher than IFN α (5.2%; 95%CI, 3.7-6.8) and IFN β (7.0%; 95%CI, 0.06-23.92). IFN α+RBV treated patients experienced hyperthyroidism in 5.0% (95%CI, 3.6-6.5), which was higher than IFN α (3.5%; 95%CI, 2.5-4.8) and IFN β (3.4%; 95%CI, 0.9-7.5). The summary estimated incidence of painless thyroiditis was 5.8% (95%CI, 2.8-9.8) for IFN α, and 3.5% (95%CI,1.9-5.5) for IFN α+RBV. The summary estimated incidence of diabetes was 1.4% (95%CI, 0.3-3.1) for IFN, 0.55% (95%CI, 0.05-1.57) for IFN α, 3.3% (95%CI,1.1-6.6) for IFN α+RBV.ConclusionsOur meta-analysis shows a high incidence of endocrine adverse events provoked by IFN, further reinforced by combined RBV treatment.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022334131.

Keywords